Search for a trial

Beta-alanine supplementation in patients with COPD receiving non-linear periodized exercise (NLPE) training: randomized placebo-controlled trial.

The primary objective is to compare the effects of daily beta-alanine supplementation or a placebo supplement on exercise tolerance (walking endurance time) in patients with COPD receiving NLPE.The secondary objectives are:• to determine the effects…

The effect of targeted nutrient supplementation on physical activity and health related quality of life in COPD

To investigate the efficacy of targeted nutrient supplementation on daily physical activity level as well as generic health status in patients with moderate to very severe COPD. Additionally, we aim to disentangle the relative effect of targeted…

Nasal High-Flow Therapy to treat COPD exacerbations: a matter of monitoring and controlling settings?

The aim of the present study is to prove efficacy of nHFT in enhancing recovery from COPD exacerbations. We aim to improve the effectiveness of nHFT by developing new technologies to control and monitor the effect of nHFT and by providing background…

An innovative breath test for better care for children with asthma-like symptoms, ADEM2 (Asthma Diagnosis with Exhaled Markers)

Objectives: 1) The development of an optimal point-of-care (POC) breath test for an early asthma diagnosis in preschool wheezing children; 2) To unravel important pathogenetic mechanisms in the early development of viral wheeze and asthma by…

PHASE Ib, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY OF SELNOFLAST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Primary: To assess the safety profile of selnoflast compared with that of placeboSecondary: - To evaluate the efficacy of selnoflast compared with that of placebo- To assess the pharmacokinetic properties of selnoflast and metabolite(s) as…

Evaluation of different treatment thresholds in a clinical pathway for children with acute asthma

Evaluation of the effect of different treatment thresholds in a clinical pathway for children with acute asthma who are treated with supplemental oxygen

A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis.

This study has been transitioned to CTIS with ID 2023-510174-13-00 check the CTIS register for the current data. The objective of the proposed study is to confirm the findings of the dose finding trial by, primarily, assessing the effect of two…

Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection

- In silico definition of the most optimal posaconazole dose for children and adolescents with CF aged 8 to 17 years.- Assess the prevalence of Aspergillus infection in children and adolescents with CF aged 8 -17 years.- An intensive sampling…

Beta-Alanine Supplementation in patients with COPD following an exercise training program to strengthen the lower limbs.

The primary objective is to compare the effects of daily beta-alanine supplementation or a placebo supplement on exercise tolerance (cycle endurance time). The secondary objectives are:1) To compare the effects of daily oral beta-alanine…

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease

This study has been transitioned to CTIS with ID 2023-507093-40-00 check the CTIS register for the current data. EFFICACY OBJECTIVESThe primary efficacy objective for this study is to evaluate the efficacy of astegolimab compared with placebo The…

A 52-week, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.

This study has been transitioned to CTIS with ID 2023-510175-60-00 check the CTIS register for the current data. The objective of the proposed study is to confirm the findings of the dose ranging trial by, primarily, assessing the effect of two…

Effect of Reslizumab on small airways in asthma. RESSAPEA

To investigate the effect the effect of a 3-months treatment with Reslizumab on small airways function in patients with severe eosinophilic asthma, and to relate the changes in small airway function to changes in asthma symptoms and quality of life.

A multi-center, randomized, double-blind, parallel-group, placebo controlled
study of mepolizumab 100 mg SC as add-on treatment in participants with
COPD experiencing frequent exacerbations and characterized by eosinophil levels (Study 208657)

Primary objective:To evaluate the efficacy of mepolizumab 100 mg subcutaneous (SC) compared to placebo, given every 4 weeks in liquid formulation by safety syringe (SS) to COPD participants at high risk ofexacerbations despite the use of optimized…

Triple therapy effectiveness in COPD patients with characteristics of asthma: A pragmatic Primary Care trial - The TRACkER trial

This study has been transitioned to CTIS with ID 2023-508300-37-00 check the CTIS register for the current data. To investigate the effectiveness of triple therapy (ICS/ long-acting beta 2 agonist (LABA)/long-acting muscarine antagonist (LAMA)) on…

Pharmacogenetics Use For Further treatment Improvement in childreN

To assess whether ADRB2 genotype-guided asthma treatment in children with persistend athma symptoms despite ICS treatment leads to better asthma control compared to non-genotype-guided asthma treatment.

Anti-inflammatory effects of tiotropium in patients with stable COPD-A randomized controlled double-blind study

This research proposal aims to assess the anti-inflammatory effects after 6 weeks treatment with tiotropium compared to placebo in patients with stable COPD.

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

In this trial, the researchers want to know how safe AZD8630 is and how well it works to control asthma symptoms when taken with the Saphira inhaler alongside their standard medication. Saphira is a new device that has been designed to deliver…

The Rainbow Study - A Randomized Controlled Trial to Evaluate the effect of Personalized Feedback on Symptom Perception in Asthmatic Children

Primary objective :How does measuring lung function and VAS at home with personalized feedback based on the Rainbow tool influence the perception of asthma related symptoms of asthmatic children? Secundary objectives: -Is there an additional effect…

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week
Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in
Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease
(COPD) with Type 2 inflammation

- The purpose of this study is to evaluate the efficacy of the study drug to lung function, exacerbations and quality of life with patients with COPD. The safety and tolerability of the study drug is monitored as part of this study.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study

1. To evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period